Vitamin D3 Decreases Parathyroid Hormone in HIV-infected Youth Being Treated with Tenofovir: a Randomized, Placebo-controlled Trial

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2012 Jan 24

PMID 22267714

Citations 42

Authors

Peter L Havens

Charles B Stephensen

Rohan Hazra

Patricia M Flynn

Craig M Wilson

Brandy Rutledge

James Bethel

Cynthia G Pan

Leslie R Woodhouse

Marta D Van Loan

Nancy Liu

Jorge Lujan-Zilbermann

Alyne Baker

Bill G Kapogiannis

Kathleen Mulligan

Affiliations

Soon will be listed here.

Abstract

Background: The study goal was to determine the effect of vitamin D (VITD) supplementation on tubular reabsorption of phosphate (TRP), parathyroid hormone (PTH), bone alkaline phosphatase (BAP), and C-telopeptide (CTX) in youth infected with human immunodeficiency virus (HIV) receiving and not receiving combination antiretroviral therapy (cART) containing tenofovir disoproxil fumarate (TDF).

Methods: This randomized, double-blind, placebo-controlled multicenter trial enrolled HIV-infected youth 18-25 years based on stable treatment with cART containing TDF (n = 118) or no TDF (noTDF; n = 85), and randomized within those groups to vitamin D3, 50 000 IU (n = 102) or placebo (n = 101), administered at 0, 4, and 8 weeks. Outcomes included change in TRP, PTH, BAP, and CTX from baseline to week 12 by TDF/noTDF; and VITD/placebo.

Results: At baseline, VITD and placebo groups were similar except those on TDF had lower TRP and higher PTH and CTX. At week 12, 95% in the VITD group had sufficient serum 25-hydroxy vitamin D (25-OHD; ≥20 ng/mL), increased from 48% at baseline, without change in placebo (P < .001). PTH decreased in the TDF group receiving VITD (P = .031) but not in the noTDF group receiving VITD, or either placebo group. The decrease in PTH with VITD in those on TDF occurred with insufficient and sufficient baseline 25-OHD (mean PTH change, -7.9 and -6.2 pg/mL; P = .031 and .053, respectively).

Conclusions: In youth on TDF, vitamin D3 supplementation decreased PTH, regardless of baseline 25-OHD concentration.

Clinical Trials Registration: NCT00490412.

Citing Articles

Association between calcium and vitamin D supplementation and increased risk of kidney stone formation in patients with osteoporosis in Southwest China: a cross-sectional study.

Shi L, Bao Y, Deng X, Xu X, Hu J BMJ Open. 2025; 15(2):e092901.

PMID: 39956606 PMC: 11831308. DOI: 10.1136/bmjopen-2024-092901.

Tenofovir induced Fanconi syndrome in a middle age African female from Kenya, East Africa: Case report and brief literature review.

Odhiambo F, Nareeba S, Mwangeka G, Njambi A, Nyakebati V Clin Case Rep. 2024; 12(6):e8889.

PMID: 38799537 PMC: 11126650. DOI: 10.1002/ccr3.8889.

Bone Health in People Living with HIV/AIDS: An Update of Where We Are and Potential Future Strategies.

Ahmed M, Mital D, Abubaker N, Panourgia M, Owles H, Papadaki I Microorganisms. 2023; 11(3).

PMID: 36985362 PMC: 10052733. DOI: 10.3390/microorganisms11030789.

Tenofovir-induced osteopenia and hyperparathyroidism: A case report and literature review.

Zeng J, Ye P, Wei D, Li L, Ma W Front Endocrinol (Lausanne). 2023; 13:1043954.

PMID: 36714555 PMC: 9875041. DOI: 10.3389/fendo.2022.1043954.

Osteoporosis and HIV Infection.

Biver E Calcif Tissue Int. 2022; 110(5):624-640.

PMID: 35098324 PMC: 9013331. DOI: 10.1007/s00223-022-00946-4.

References

Essig M, Duval X, Kaied F, Iordache L, Gervais A, Longuet P . Is phosphatemia the best tool to monitor renal tenofovir toxicity?. J Acquir Immune Defic Syndr. 2007; 46(2):256-8. DOI: 10.1097/QAI.0b013e3181142f31. View

von Borstel Smith M, Crofoot K, Rodriguez-Proteau R, Filtz T . Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells. Toxicol In Vitro. 2007; 21(5):855-62. DOI: 10.1016/j.tiv.2007.02.008. View

Marks K, Kilav R, Naveh-Many T, Silver J . Calcium, phosphate, vitamin D, and the parathyroid. Pediatr Nephrol. 1996; 10(3):364-7. DOI: 10.1007/BF00866787. View

Armas L, Hollis B, Heaney R . Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004; 89(11):5387-91. DOI: 10.1210/jc.2004-0360. View

Fux C, Rauch A, Simcock M, Bucher H, Hirschel B, Opravil M . Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther. 2009; 13(8):1077-82. View

Sims N, Gooi J . Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol. 2008; 19(5):444-51. DOI: 10.1016/j.semcdb.2008.07.016. View

Judd A, Boyd K, Stohr W, Dunn D, Butler K, Lyall H . Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010; 24(4):525-34. DOI: 10.1097/QAD.0b013e3283333680. View

Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

Stephensen C, Marquis G, Kruzich L, Douglas S, Aldrovandi G, Wilson C . Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006; 83(5):1135-41. DOI: 10.1093/ajcn/83.5.1135. View

10.

Grigsby I, Pham L, Mansky L, Gopalakrishnan R, Carlson A, Mansky K . Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun. 2010; 394(1):48-53. PMC: 2847063. DOI: 10.1016/j.bbrc.2010.02.080. View

11.

Kiser J, Fletcher C, Flynn P, Cunningham C, Wilson C, Kapogiannis B . Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007; 52(2):631-7. PMC: 2224775. DOI: 10.1128/AAC.00761-07. View

12.

Razzaque M . The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol. 2009; 5(11):611-9. PMC: 3107967. DOI: 10.1038/nrendo.2009.196. View

13.

Fux C, Christen A, Zgraggen S, Mohaupt M, Furrer H . Effect of tenofovir on renal glomerular and tubular function. AIDS. 2007; 21(11):1483-5. DOI: 10.1097/QAD.0b013e328216f15b. View

14.

Lee R, Lyles K, Colon-Emeric C . A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother. 2010; 8(1):34-46. PMC: 3570810. DOI: 10.1016/j.amjopharm.2010.02.003. View

15.

Cummings S, Block G, McHenry K, Baron R . Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol. 1987; 126(5):796-802. DOI: 10.1093/oxfordjournals.aje.a114716. View

16.

Grigsby I, Pham L, Gopalakrishnan R, Mansky L, Mansky K . Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts. Biochem Biophys Res Commun. 2009; 391(3):1324-9. PMC: 2812596. DOI: 10.1016/j.bbrc.2009.12.039. View

17.

Stellbrink H, Orkin C, Arribas J, Compston J, Gerstoft J, Van Wijngaerden E . Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010; 51(8):963-72. DOI: 10.1086/656417. View

18.

Suda T, Ueno Y, Fujii K, Shinki T . Vitamin D and bone. J Cell Biochem. 2003; 88(2):259-66. DOI: 10.1002/jcb.10331. View

19.

Heaney R, Armas L, Shary J, Bell N, Binkley N, Hollis B . 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr. 2008; 87(6):1738-42. DOI: 10.1093/ajcn/87.6.1738. View

20.

Kinai E, Hanabusa H . Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009; 25(4):387-94. DOI: 10.1089/aid.2008.0202. View